KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Non-Current Assets: 2009-2024

Historic Non-Current Assets for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Dec 2024 value amounting to $3.8 billion.

  • Biomarin Pharmaceutical's Non-Current Assets fell 0.90% to $3.8 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $3.8 billion, marking a year-over-year decrease of 0.90%. This contributed to the annual value of $3.8 billion for FY2024, which is 3.32% down from last year.
  • Biomarin Pharmaceutical's Non-Current Assets amounted to $3.8 billion in FY2024, which was down 3.32% from $3.9 billion recorded in FY2023.
  • Biomarin Pharmaceutical's 5-year Non-Current Assets high stood at $3.9 billion for FY2023, and its period low was $3.5 billion during FY2020.
  • Over the past 3 years, Biomarin Pharmaceutical's median Non-Current Assets value was $3.8 billion (recorded in 2024), while the average stood at $3.8 billion.
  • In the last 5 years, Biomarin Pharmaceutical's Non-Current Assets climbed by 27.58% in 2020 and then decreased by 3.32% in 2024.
  • Yearly analysis of 5 years shows Biomarin Pharmaceutical's Non-Current Assets stood at $3.5 billion in 2020, then increased by 6.41% to $3.7 billion in 2021, then dropped by 2.86% to $3.6 billion in 2022, then rose by 7.23% to $3.9 billion in 2023, then declined by 3.32% to $3.8 billion in 2024.